Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Schaeffer

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Geobiology|October 15, 2013
Record of archaeal activity at the serpentinite-hosted Lost City Hydrothermal FieldS Méhay, G L Früh-Green, S Q Lang, et al.
Journal of Cardiovascular Pharmacology|August 7, 2001
Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient miceF Dol, G Martin, B Staels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Telomerase RNA as a detection marker in the serum of breast cancer patientsX Q Chen, H Bonnefoi, M F Pelte, et al.
The American Journal of Physiology|January 1, 1995
Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cellsC Serradeil-Le Gal, J M Herbert, C Delisee, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 19, 2008
Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processesO Kunduzova, N Alet, N Delesque-Touchard, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2003
Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitorJ Lorrain, L Millet, I Lechaire, et al.
Thrombosis and Haemostasis|April 20, 2001
Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonistC N Berry, J Lorrain, S Lochot, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 24, 1999
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studiesE Bignon, A Bachy, R Boigegrain, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Geobiology|October 15, 2013
Record of archaeal activity at the serpentinite-hosted Lost City Hydrothermal FieldS Méhay, G L Früh-Green, S Q Lang, et al.
Journal of Cardiovascular Pharmacology|August 7, 2001
Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient miceF Dol, G Martin, B Staels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Telomerase RNA as a detection marker in the serum of breast cancer patientsX Q Chen, H Bonnefoi, M F Pelte, et al.
The American Journal of Physiology|January 1, 1995
Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cellsC Serradeil-Le Gal, J M Herbert, C Delisee, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 19, 2008
Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processesO Kunduzova, N Alet, N Delesque-Touchard, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 23, 2003
Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitorJ Lorrain, L Millet, I Lechaire, et al.
Thrombosis and Haemostasis|April 20, 2001
Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonistC N Berry, J Lorrain, S Lochot, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 24, 1999
SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studiesE Bignon, A Bachy, R Boigegrain, et al.
Pageof 6